Howard Horn insider trades: Ultragenyx Pharmaceutical (RARE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Howard reports to the SEC
Open-market buys and sales
20 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | RARE | ↓ Sell | 7,066 | $15.27 | $108K | Direct | Oct 19, 2026 (4d) |
| Aug 3, 2026 | RARE | ↓ Sell | 4,696 | $24.92 | $117K | Direct | Aug 4, 2026 (1d) |
| Jul 1, 2026 | RARE | ↓ Sell | 4,698 | $33.13 | $156K | Direct | Jul 6, 2026 (5d) |
| May 1, 2026 | RARE | ↓ Sell | 4,683 | $24.90 | $117K | Direct | May 4, 2026 (3d) |
| Apr 1, 2026 | RARE | ↓ Sell | 4,683 | $20.97 | $98K | Direct | Apr 2, 2026 (1d) |
| Mar 3, 2026 | RARE | ↓ Sell | 10,044 | $22.65 | $228K | Direct | Mar 3, 2026 (0d) |
| Feb 2, 2026 | RARE | ↓ Sell | 3,061 | $23.56 | $72K | Direct | Feb 3, 2026 (1d) |
| Jan 2, 2026 | RARE | ↓ Sell | 3,150 | $22.84 | $72K | Direct | Jan 5, 2026 (3d) |
| Dec 10, 2025 | RARE | ↓ Sell | 3,081 | $36.38 | $112K | Direct | Dec 11, 2025 (1d) |
| Oct 13, 2025 | RARE | ↓ Sell | 7,942 | $31.51 | $250K | Direct | Oct 14, 2025 (1d) |
| Mar 6, 2025 | RARE | ↓ Sell | 1,785 | $40.40 | $72K | Direct | Mar 10, 2025 (4d) |
| Oct 10, 2024 | RARE | ↓ Sell | 7,465 | $52.76 | $394K | Direct | Oct 11, 2024 (1d) |
| Feb 23, 2023 | VIR | ↓ Sell | 2,248 | $25.97 | $58K | Direct | Feb 24, 2023 (1d) |
| Feb 17, 2023 | VIR | ↓ Sell | 2,424 | $25.29 | $61K | Direct | Feb 21, 2023 (4d) |
| Feb 17, 2022 | VIR | ↓ Sell | 2,393 | $31.93 | $76K | Direct | Feb 22, 2022 (5d) |
| Jul 13, 2020 | VIR | ↓ Sell | 30,000 | $50.06 | $1.5M | Direct | Jul 15, 2020 (2d) |
| Jul 2, 2020 | VIR | ↓ Sell | 20,000 | $38.92 | $778K | Direct | Jul 2, 2020 (0d) |
| Jun 25, 2020 | VIR | ↓ Sell | 30,000 | $50.00 | $1.5M | Direct | Jun 26, 2020 (1d) |
| Jun 19, 2020 | VIR | ↓ Sell | 10,000 | $40.00 | $400K | Direct | Jun 23, 2020 (4d) |
| Jun 1, 2020 | VIR | ↓ Sell | 10,000 | $35.10 | $351K | Direct | Jun 2, 2020 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RARE insiders
Open-market trades in the last 12 months
About Howard Horn's insider trades
Howard Horn is Chief Financial Officer at Ultragenyx Pharmaceutical (RARE). Since Jun 1, 2020, Howard has reported no open-market purchases and 20 sales worth $6.5M on SEC Form 4. In the last 12 months: 9 sales ($1.1M).
Their filings also include grants and awards (8 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RARE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.